Agmatine
Based on 1 publication(s) in Google Scholar
Agmatine is an orally active analgesic that can cross the blood-brain barrier. Agmatine targets the 5-HT2A receptor, 5-HT3 receptor, α2-adrenergic receptor, and I1 imidazoline receptor. Agmatine produces dose-dependent analgesic effects in various pain models. Agmatine can be used in research related to visceral pain, neuropathic pain, and inflammatory pain.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 306-60-5
- Formule: C5H14N4
- Masse moléculaire:130.19
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Agmatine
MoreVoir tous les produits spécifiques à Isoform 5-HT Receptor
MoreVoir tous les produits spécifiques à Isoform Adrenergic Receptor
More
Activité biologique
|
5-HT2A Receptor |
5-HT3 Receptor |
α2-adrenergic receptor |
Agmatine (10-100 mg/kg; i.p.; 30 min pre-glutamate) dose-dependently inhibits glutamate-induced paw nociception in mice with an ID50 of 19.5 mg/kg (i.p.)[2].
Agmatine (3-100 mg/kg; i.p.; 30 min pre-capsaicin) dose-dependently inhibits Capsaicin (HY-10448)-induced paw nociception in mice with an ID50 of 43.7 mg/kg (i.p.)[2].
Agmatine (1-100 mg/kg; i.p.; 30 min pre-formalin; 10 mg/kg; i.p.; 10 min pre-formalin; 10 mg/kg; i.p.; 5 min post-formalin) dose-dependently inhibits both neurogenic and inflammatory phases of formalin-induced paw nociception in mice, with greater potency against the inflammatory phase (ID50 5.6 mg/kg i.p.) than the neurogenic phase (ID50 13.7 mg/kg i.p.)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (both sexes, 25-35 g)[2]
-
Dosage:1-30 mg/kg (i.p.); 10-300 mg/kg (p.o.)
-
Administration:i.p. (30 min pre-acetic acid; 0.5, 1, 2, 4, or 6 hours pre-acetic acid); p.o. (60 min pre-acetic acid)
-
Result:Produced dose-dependent inhibition of acetic acid-induced abdominal constrictions, with an ID50 of 5.6 mg/kg (i.p.) and 147.3 mg/kg (p.o.), achieving maximum inhibitions of 83% and 57%, respectively.
Produced significant antinociception starting at 30 minutes post-administration with 10 mg/kg i.p., which persisted for up to 4 hours.
Had its antinociceptive effect completely reversed by pre-treatment with L-arginine (600 mg/kg i.p.), naloxone (1 mg/kg i.p.), yohimbine (0.15 mg/kg i.p.), ketanserin (0.3 mg/kg i.p.), ondansetron (0.5 mg/kg i.p.), or efaroxan (1 mg/kg i.p.), but not by D-arginine (600 mg/kg i.p.), pindolol (1 mg/kg i.p.), idazoxan (3 mg/kg i.p.), or neonatal capsaicin treatment.
Had its antinociceptive effect significantly reversed by pre-treatment with p-chlorophenylalanine methyl ester (100 mg/kg i.p. once daily for 4 days).
-
Animal Model:Swiss mice (both sexes, 25-35 g)[2]
-
Dosage:10-100 mg/kg
-
Administration:i.p. (30 min pre-glutamate)
-
Result:Produced dose-dependent inhibition of glutamate-induced paw licking, with an ID50 of 19.5 mg/kg and a maximum inhibition of 76%.
-
Animal Model:Swiss mice (both sexes, 25-35 g)[2]
-
Dosage:3-100 mg/kg
-
Administration:i.p. (30 min pre-capsaicin)
-
Result:Produced dose-dependent inhibition of capsaicin-induced paw licking, with an ID50 of 43.7 mg/kg and a maximum inhibition of 55%.
-
Animal Model:Swiss mice (both sexes, 25-35 g)[2]
-
Dosage:1-100 mg/kg (30 min pre-formalin); 10 mg/kg (10 min pre-formalin); 10 mg/kg (5 min post-formalin)
-
Administration:i.p. (30 min pre-formalin; 10 min pre-formalin; 5 min post-formalin)
-
Result:Produced dose-dependent inhibition of both formalin-induced pain phases, with ID50 values of 13.7 mg/kg (neurogenic phase, maximum inhibition 65%) and 5.6 mg/kg (inflammatory phase, maximum inhibition 76%).
Inhibited the neurogenic phase significantly when administered 10 mg/kg i.p. 10 minutes pre-formalin.
Inhibited the inflammatory phase by 42% when administered 10 mg/kg i.p. 5 minutes post-formalin.
Inhibited the inflammatory phase by 56% when administered 10 mg/kg i.p. 30 minutes pre-formalin.
Chemical Information
-
CAS No. 306-60-5
-
Appearance Solid
-
Masse moléculaire 130.19
-
Formule C5H14N4
-
Color White to off-white
-
SMILES
NC(NCCCCN)=N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Psychopharmacology (Berl)
Agmatine ameliorates morphine-induced behavioral sensitization through blood-brain barrier protection and anti-neuroinflammatory effects in the nucleus accumbens. [Abstract]2025 Oct 24. PMID: 41134339
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Agmatine Related Classifications
HY-WAA0304 Related Classifications
Powered by Bioz